SCHEMBL25959092

SCHEMBL25959092

Cc1cccc(-c2csc(Nc3ccccc3)n2)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 12/20 0.68
KMT2A Q03164 11/20 0.68
MEN1 O00255 10/20 0.68
MAPT P10636 8/20 0.68
MAPK1 P28482 1/20 0.68
HTT P42858 1/20 0.68
HDAC6 Q9UBN7 1/20 0.68
CSNK2A1 P68400 1/20 0.64
ALOX5 P09917 5/20 0.64
SMN1; SMN2 Q16637 5/20 0.64
NPC1 O15118 8/20 0.63
GAA P10253 5/20 0.63
ALDH1A1 P00352 4/20 0.63
NPSR1 Q6W5P4 1/20 0.63
VCP P55072 2/20 0.61
NPY5R Q15761 1/20 0.61
AMY1A P0DUB6 1/20 0.61
NFKB1 P19838 2/20 0.60
NFKB2 Q00653 2/20 0.60
RELA Q04206 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18769586 0.93 MEN1 (0.79) RAB9AKMT2AMEN1MAPTMAPK1
SCHEMBL12298108 0.89 MEN1 (0.78) RAB9AKMT2AMEN1MAPTMAPK1
SCHEMBL25959168 0.87 RAB9A (0.64) RAB9AKMT2AMEN1MAPTMAPK1
SCHEMBL26307375 0.86 CFTR (0.70) RAB9AKMT2AMEN1MAPTMAPK1
SCHEMBL25959109 0.86 CYP1A1 (0.70) RAB9AKMT2AMEN1MAPTMAPK1
SCHEMBL1822611 0.86 SMN1; SMN2 (0.84) RAB9AKMT2AMEN1MAPTHTT
SCHEMBL22560266 0.86 RAB9A (0.73) RAB9AKMT2AMEN1MAPTMAPK1
SCHEMBL1819906 0.85 RAB9A (0.78) RAB9AKMT2AMEN1MAPTMAPK1
SCHEMBL10072694 0.85 ALOX5 (0.74) RAB9AKMT2AMEN1MAPTMAPK1
SCHEMBL23553571 0.84 MAPT (0.74) RAB9AKMT2AMEN1MAPTCSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230286933-A1 2,5-ARYL-THIAZOLE ANALOGS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SOUTHERN RES INST (US) 2023-09-14 US disclosed
US-11718593-B2 2,5-aryl-thiazole analogs for the treatment of neurodegenerative diseases SOUTHERN RESEARCH INSTITUTE (US) 2023-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718593-B2 2,5-aryl-thiazole analogs for the treatment of neurodegenerative diseases SMN1; SMN2, TDP2, TDP1 RAB9A 2604/4885KMT2A 1259/4885MEN1 4743/4885
US-20230286933-A1 2,5-ARYL-THIAZOLE ANALOGS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SMN1; SMN2, TDP2, TDP1 RAB9A 2604/4885KMT2A 1259/4885MEN1 4743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.